研究关注：Bayer to Acquire Perfuse for up to $2.45B, Seeing Ophthalmology Opportunity

## 事件概览

Bayer’s ophthalmology pipeline has long been dominated by the blockbuster drug Eylea ® (aflibercept), co-marketed with Regeneron Pharmaceuti...

## 核心信息

Bayer’s ophthalmology pipeline has long been dominated by the blockbuster drug Eylea ® (aflibercept), co-marketed with Regeneron Pharmaceuticals and initially approved in 2011. However, Eylea is close to losing exclusivity for key U.S. patents. The post Bayer to Acquire Perfuse for up to $2.45B, Seeing Ophthalmology Opportunity appeared first on GEN - Genetic Engineering and Biotechnology News .

## 为什么值得关注

这条内容与 drug discovery 相关，可能影响科研选题、技术趋势判断或产业观察。BioDir 已根据来源、摘要长度、主题词和潜在影响给出 39 分的候选评分。

## 发布提示

发布前应核对原文链接、研究对象、样本规模、方法限制和结论边界。若来源为 bioRxiv 或 medRxiv，应明确标注其为预印本，尚未经过同行评议。